Pierre Lafolie

Publications
CV
Public outreach and news

Articles

Article: THERAPEUTIC DRUG MONITORING. 2016;38(2):239-245
Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Ostervall J; Hatschek T; Vitols S
Article: LAKARTIDNINGEN. 2015;112:C9CL
[Ethical review of research in the grey area. The Ethical Review Act should be widened and case management more efficient].
Lafolie P; Agahi N
Article: VACCINE. 2014;32(45):5967-5974
Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I/IIa clinical trial
Neimert-Andersson T; Binnmyr J; Enoksson M; Langeback J; Zettergren L; Hallgren A-C; Franzen H; Enoksson SL; Lafolie P; Lindberg A; Al-Tawil N; Andersson M; Singer P; Gronlund H; Gafvelin G
Article: SCANDINAVIAN JOURNAL OF UROLOGY. 2013;47(6):503-508
Nitric oxide as a marker for evaluation of treatment effect of cyclosporine A in patients with bladder pain syndrome/interstitial cystitis type 3C
Ehren I; Grufman KH; Vrba M; Sundelin R; Lafolie P
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2013;437(2):280-286
Differential role of thiopurine methyltransferase in the cytotoxic effects of 6-mercaptopurine and 6-thioguanine on human leukemia cells
Karim H; Ghalali A; Lafolie P; Vitols S; Fotoohi AK
Article: CURRENT DRUG DELIVERY. 2013;10(4):404-412
Comparison of Uptake Mechanisms for Anthracyclines in Human Leukemic Cells
Karim H; Bogason A; Bhuiyan H; Fotoohi AK; Lafolie P; Vitols S
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2011;71(4):514-521
Inverse relationship between leukaemic cell burden and plasma concentrations of daunorubicin in patients with acute myeloid leukaemia
Bogason A; Quartino AL; Lafolie P; Masquelier M; Karlsson MO; Paul C; Gruber A; Vitols S
Article: DRUG METABOLISM LETTERS. 2010;4(4):228-232
Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
Bogason A; Masquelier M; Lafolie P; Skogastierna C; Paul C; Gruber A; Vitols S
Article: LAKARTIDNINGEN. 2010;107(40):2384-2385
[EU strikes hard against clinical research--an EU project ECRIN builds bridges for clinical trials].
Johansson H; Souri P; Lafolie P
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2010;54(4):435-441
Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children
Lundeberg S; Stephanson N; Lafolie P; Olsson GL; Stiller C-O; Eksborg S
Article: LAKARTIDNINGEN. 2009;106(5):279-281
[Research without ethical approval occurs--often negligence behind. Review of Karolinska Institute's publications 2006].
Lindelöf B; Lafolie P; Asp P; Forssberg O
Article: PHYTOMEDICINE. 2008;15(6-7):391-399
Efficacy of the natural antioxidant astaxanthin in the treatment of functional dyspepsia in patients with or without Helicobacter pylori infection:: A prospective, randomized, double blind, and placebo-controlled study
Kupcinskas L; Lafolie P; Lignell A; Kiudelis G; Jonaitis L; Adamonis K; Andersen LP; Wadstrom T
Journal article: INVESTIGATIVE UROLOGY. 2007;177(4):41
120: Nitric Oxide as a Marker for Evaluation of Treatment Efficacy of Ciclosporin in Patients with Classic Interstitial Cystitis
Ehren I; Vrba M; Lafolie P
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2007;51(3):322-330
The addition of tramadol to morphine via patient-controlled analgesia does not lead to better post-operative pain relief after total knee arthroplasty
Stiller C-O; Lundblad H; Weidenhielm L; Tullberg T; Grantinger B; Lafolie P; Jansson K-A
Article: SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY. 2007;41(4):335-340
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: A randomized, placebo-controlled, double-blind study
Ehren I; Volz D; Farrelly E; Berglund L; Brundin L; Hultling C; Lafolie P
Article: LAKARTIDNINGEN. 2006;103(15-16):1169-1170
[Why has the drug trial at Northwick Park Hospital turned out to a disaster?].
Lafolie P
Journal article: EUROPEAN UROLOGY OPEN SCIENCE. 2006;5(2):299
TREATMENT WITH BOTULINUS TOXIN A IN NEUROGENIC BLADDER DYSFUNCTION -A RANDOMISED DOUBLE-BLIND STUDY WITH DYSPORT
Ehren I; Volz D; Farrelly E; Berglund L; Brundin L; Lafolie P
Article: LAKARTIDNINGEN. 2006;103(4):225
[Now no new drugs will be developed!].
Lafolie P
Article: LAKARTIDNINGEN. 2004;101(10):917-920
[More stringent requirements concerning clinical research. The new EU rules come into effect on May 1].
Lafolie P
Article: LAKARTIDNINGEN. 2002;99(51-52):5180-5181
[Reporting of approval by research ethics committee and informed consent should be included in scientific information. A neglected quality indicator].
Lafolie P
Article: LAKARTIDNINGEN. 2002;99(30-31):3132-3134
[Epidemiology versus clinical trial. A five-round-match on scientific reliability].
Lafolie P
Article: LAKARTIDNINGEN. 2000;97(37):4020-4021
[Alarm from expert meeting when it comes to Swedish clinical research. "We are no longer as good as our reputation used to be"].
Lafolie P; Wallentin L
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 2000;35(5):464-469
Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers -: A gastroscopic study
Fork FT; Lafolie P; Tóth E; Lindgärde F
Article: JOURNAL OF ANALYTICAL TOXICOLOGY. 1996;20(7):541-546
Urine and plasma pharmacokinetics of codeine in healthy volunteers: Implications for drugs-of-abuse testing
Lafolie P; Beck O; Lin Z; Albertioni F; Boreus L
Journal article: THERAPEUTIC DRUG MONITORING. 1995;17(4):423
162 URINE PHARMACOKINETICS OF CODEINE IN HEALTHY VOLUNTEERS
Beck O; Lafolie P; Lin Z; Boreus LO
Article: PSYCHOPHARMACOLOGY. 1995;118(2):122-126
SUBJECTIVE AND OBJECTIVE SYMPTOMS IN RELATION TO PLASMA METHADONE CONCENTRATION IN METHADONE PATIENTS
HILTUNEN AJ; LAFOLIE P; MARTEL J; OTTOSSON EC; BOREUS LO; BECK O; BORG S; HJEMDAHL P
Journal article: JOURNAL OF ANALYTICAL TOXICOLOGY. 1994;18(3):129-133
EVALUATION OF ANALYTICAL PROCEDURES FOR URINARY CODEINE AND MORPHINE MEASUREMENTS
ZHEN L; LAFOLIE P; BECK O
Journal article: SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION. 1994;54(3):251-256
DEFICIENT PERFORMANCE OF DRUGS OF ABUSE TESTING IN SWEDEN - AN EXTERNAL CONTROL STUDY
LAFOLIE P; BECK O
Journal article: CLINICAL CHEMISTRY. 1994;40(1):170-171
USING RELATION BETWEEN URINARY CANNABINOID AND CREATININE EXCRETIONS TO IMPROVE MONITORING OF ABUSER ADHERENCE TO ABSTINENCE
LAFOLIE P; BECK O; HJEMDAHL P; BORG S
Journal article: LAKARTIDNINGEN. 1993;90(45):3954-3957
[Benzodiazepine findings in autopsy material. A study shows interacting factors in fatal cases].
Ericsson HR; Holmgren P; Jakobsson SW; Lafolie P; De Rees B
Journal article: CLINICAL CHEMISTRY. 1993;39(6):1352-1353
MODIFICATION OF COMMERCIAL ASSAY KITS IS JUSTIFIED
BECK O; LAFOLIE P; HJEMDAHL P
Journal article: CLINICAL TRANSPLANTATION. 1993;7(1pt1):65-70
Large interindividual variability in bioavailability of azathioprine in renal transplant recipients
Ohlman S; Lafolie P; Lindholm A; Liliemark J; Tydén G; Peterson C
Journal article: CLINICAL CHEMISTRY. 1993;39(4):699
MEASUREMENT OF CREATININE IN URINE SCREENING FOR DRUGS OF ABUSE - REPLY
LAFOLIE P
Journal article: CLINICAL CHEMISTRY. 1992;38(2):271-275
DETECTION OF BENZODIAZEPINE INTAKE IN THERAPEUTIC DOSES BY IMMUNOANALYSIS OF URINE - 2 TECHNIQUES EVALUATED AND MODIFIED FOR IMPROVED PERFORMANCE
BECK O; LAFOLIE P; HJEMDAHL P; BORG S; ODELIUS G; WIRBING P
Journal article: NORDISK MEDICIN. 1992;107(12):323-325
[Diagnosis in acute narcotics poisoning].
Lafolie P; Myrenfors P
Journal article: CLINICAL CHEMISTRY. 1991;37(11):1927-1931
IMPORTANCE OF CREATININE ANALYSES OF URINE WHEN SCREENING FOR ABUSED DRUGS
LAFOLIE P; BECK O; BLENNOW G; BOREUS L; BORG S; ELWIN CE; KARLSSON L; ODELIUS G; HJEMDAHL P
Journal article: LAKARTIDNINGEN. 1991;88(40):3290-3294
[Use and abuse of substance abuse analyses in urine].
Lafolie P; Beck O; Boréus L; Hjemdahl P; Borg S; Rydberg U
Journal article: JOURNAL OF CHROMATOGRAPHY - BIOMEDICAL APPLICATIONS. 1991;570(1):198-202
CHIRAL ANALYSIS OF METHADONE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
BECK O; BOREUS LO; LAFOLIE P; JACOBSSON G
Journal article: LAKARTIDNINGEN. 1991;88(17):1570
[Analyses in suspected abuse should be used carefully].
Lafolie P
Journal article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1991;40(6):599-601
INTRAINDIVIDUAL VARIATION IN 6-MERCAPTOPURINE PHARMACOKINETICS DURING ORAL-MAINTENANCE THERAPY OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
LAFOLIE P; HAYDER S; BJORK O; PETERSON C
Journal article: THERAPEUTIC DRUG MONITORING. 1990;12(5):473-477
MONITORING OF PLASMA METHADONE - INTERCORRELATION BETWEEN IMMUNOASSAY AND GAS-CHROMATOGRAPHY MASS-SPECTROMETRY
BECK O; BOREUS LO; BORG S; JACOBSSON G; LAFOLIE P; STENSIO M
Journal article: ACTA PAEDIATRICA SCANDINAVICA. 1990;79(8-9):832-837
THE COURSE OF BIOLOGICAL PARAMETERS AND 6-MERCAPTOPURINE PHARMACOKINETICS DURING MAINTENANCE TREATMENT OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
HAYDER S; BJORK O; LAFOLIE P
Journal article: THERAPEUTIC DRUG MONITORING. 1990;12(4):339-343
DETERMINATION OF PLASMA AZATHIOPRINE AND 6-MERCAPTOPURINE IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH ORAL AZATHIOPRINE
LILIEMARK J; PETTERSSON B; LAFOLIE P; ZWEIG T; PETERSON C
Journal article: TOXICOLOGY LETTERS. 1990;52(1):7-14
IMMUNOLOGICAL SCREENING OF BENZODIAZEPINES IN URINE - IMPROVED DETECTION OF OXAZEPAM INTAKE
BECK O; LAFOLIE P; ODELIUS G; BOREUS LO
Journal article: CANCER RESEARCH. 1990;50(1):108-112
ON THE PARADOXICALLY CONCENTRATION-DEPENDENT METABOLISM OF 6-MERCAPTOPURINE IN WEHI-3B MURINE LEUKEMIA-CELLS
LILIEMARK J; PETTERSSON B; ENGBERG B; LAFOLIE P; MASQUELIER M; PETERSON C
Journal article: THERAPEUTIC DRUG MONITORING. 1989;11(6):617-622
6-MERCAPTOPURINE PLASMA-LEVELS IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA - RELATION TO RELAPSE RISK AND MYELOTOXICITY
HAYDER S; LAFOLIE P; BJORK O; PETERSON C
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1989;6(4):259-265
VARIABILITY OF 6-MERCAPTOPURINE PHARMACOKINETICS DURING ORAL-MAINTENANCE THERAPY OF CHILDREN WITH ACUTE-LEUKEMIA
LAFOLIE P; BJORK O; HAYDER S; AHSTROM L; PETERSON C
Journal article: MEDICAL TOXICOLOGY. 1988;3(3):248-252
EXCHANGE OF CEREBROSPINAL-FLUID IN ACCIDENTAL INTRATHECAL OVERDOSE OF CYTARABINE
LAFOLIE P; LILIEMARK J; BJORK O; AMAN J; WRANNE L; PETERSON C
Journal article: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1988;5(3):187-189
6-MERCAPTOPURINE IN CEREBROSPINAL-FLUID DURING ORAL-MAINTENANCE THERAPY OF CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA
HAYDER S; LAFOLIE P; BJORK O; AHSTROM L; PETERSON C
Journal article: ACTA PAEDIATRICA SCANDINAVICA. 1986;75(5):797-803
LARGE INTERINDIVIDUAL VARIATIONS IN THE PHARMACOKINETICS OF ORAL 6-MERCAPTOPURINE IN MAINTENANCE THERAPY OF CHILDREN WITH ACUTE-LEUKEMIA AND NON-HODGKIN LYMPHOMA
LAFOLIE P; HAYDER S; BJORK O; AHSTROM L; LILIEMARK J; PETERSON C
Show more

All other publications

Book chapter: RECENT DEVELOPMENTS IN THERAPEUTIC DRUG MONITORING AND CLINICAL TOXICOLOGY. 2023;p. 513-514
Importance of Creatinine for Urine Quality Control in Determination of Abused Drugs
Lafolie P; Beck O; Blennow G; Boréus L; Borg S; Elwin C-E; Karlsson L; Odelius G; Hjemdahl P
Letter: ACTA OPHTHALMOLOGICA. 2016;94(5):e375-e376
More symptoms with sialic receptor-positive adenovirus in epidemic keratoconjunctivitis
Dahl M; Gerhardsson E; Lafolie P; Allard A; Laurell C-G
Review: CLINICAL EPIDEMIOLOGY. 2015;7:491-507
Ethical aspects of registry-based research in the Nordic countries
Ludvigsson JF; Haberg SE; Knudsen GP; Lafolie P; Zoega H; Sarkkola C; von Kraemer S; Weiderpass E; Norgaard M
Review: FRONTIERS IN PHARMACOLOGY. 2013;4:112
A European approach to clinical investigator training
Boeynaems J-M; Canivet C; Chan A; Clarke MJ; Cornu C; Daemen E; Demotes J; De Nys K; Hirst B; Hundt F; Kassai B; Kerpel-Fronius S; Kiessig L; Klech H; Kraehenbuhl J-P; Lafolie P; Lucht M; Niese D; Pauli-Magnus C; Peters B; Schaltenbrand R; Stockis A; Stykova M; Verheus N; Klingmann I
Editorial comment: NATURE REVIEWS DRUG DISCOVERY. 2013;12(6):407-408
LifeTrain: towards a European framework for continuing professional development in biomedical sciences
Hardman M; Brooksbank C; Johnson C; Janko C; See W; Lafolie P; Klech H; Verpillat P; Linden H
Letter: LAKARTIDNINGEN. 2006;103(24-25):1979
[Final reply: drug companies must be allowed to make profit].
Lafolie P
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(3):287-288
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3
Lundblad MS; Ohlsson S; Johansson P; Lafolie P; Eliasson E

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI